Developing a new class of drugs with the diversity and specificity of antibodies, coupled with the oral bioavailability of small molecules

Sectors
Healthcare
Life Sciences
First Invested
2010
Early
Company Status
IPO/Acquired
NASDAQ: RARX
Acquired by UCB